Cancer stem cell–associated miRNAs serve as prognostic biomarkers in colorectal cancer

Shusuke Toden, Shigeyasu Kunitoshi, Jacob Cardenas, Jinghua Gu, Elizabeth Hutchins, Kendall Van Keuren-Jensen, Hiroyuki Uetake, Yuji Toiyama, Ajay Goel

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Chemoresistance in cancer is linked to a subset of cancer cells termed “cancer stem cells” (CSCs), and in particular, those expressing the CD44 variant appear to represent a more aggressive disease phenotype. Herein, we demonstrate that CD44v6 represents a CSC population with increased resistance to chemotherapeutic agents, and its high expression is frequently associated with poor overall survival (OS) and disease-free survival (DFS) in patients with colorectal cancer (CRC). CD44v6+ cells showed elevated resistance to chemotherapeutic drugs and significantly high tumor initiation capacity. Inhibition of CD44v6 resulted in the attenuation of self-renewal capacity and resensitization to chemotherapeutic agents. Of note, miRNA profiling of CD44v6+ spheroid-derived CSCs identified a unique panel of miRNAs indicative of high self-renewal capacity. In particular, miR-1246 was overexpressed in CD44v6+ cells, and associated with poor OS and DFS in CRC patients. We demonstrate that CD44v6+ CSCs induced chemoresistance and enhance tumorigenicity in CRC cells, and this was in part orchestrated by a distinct panel of miRNAs with dysregulated profiles. These findings suggest that specific miRNAs could serve as therapeutic targets as well as promising prognostic biomarkers in patients with colorectal neoplasia.

Original languageEnglish
Article numbere125294
JournalJCI Insight
Volume4
Issue number6
DOIs
Publication statusPublished - Mar 21 2019
Externally publishedYes

Fingerprint

Neoplastic Stem Cells
MicroRNAs
Colorectal Neoplasms
Biomarkers
Disease-Free Survival
Neoplasms
Survival
Phenotype
Pharmaceutical Preparations
Population
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Toden, S., Kunitoshi, S., Cardenas, J., Gu, J., Hutchins, E., Van Keuren-Jensen, K., ... Goel, A. (2019). Cancer stem cell–associated miRNAs serve as prognostic biomarkers in colorectal cancer. JCI Insight, 4(6), [e125294]. https://doi.org/10.1172/jci.insight.125294

Cancer stem cell–associated miRNAs serve as prognostic biomarkers in colorectal cancer. / Toden, Shusuke; Kunitoshi, Shigeyasu; Cardenas, Jacob; Gu, Jinghua; Hutchins, Elizabeth; Van Keuren-Jensen, Kendall; Uetake, Hiroyuki; Toiyama, Yuji; Goel, Ajay.

In: JCI Insight, Vol. 4, No. 6, e125294, 21.03.2019.

Research output: Contribution to journalArticle

Toden, S, Kunitoshi, S, Cardenas, J, Gu, J, Hutchins, E, Van Keuren-Jensen, K, Uetake, H, Toiyama, Y & Goel, A 2019, 'Cancer stem cell–associated miRNAs serve as prognostic biomarkers in colorectal cancer', JCI Insight, vol. 4, no. 6, e125294. https://doi.org/10.1172/jci.insight.125294
Toden, Shusuke ; Kunitoshi, Shigeyasu ; Cardenas, Jacob ; Gu, Jinghua ; Hutchins, Elizabeth ; Van Keuren-Jensen, Kendall ; Uetake, Hiroyuki ; Toiyama, Yuji ; Goel, Ajay. / Cancer stem cell–associated miRNAs serve as prognostic biomarkers in colorectal cancer. In: JCI Insight. 2019 ; Vol. 4, No. 6.
@article{d7d840cf09254d3f958afc93a647a1e3,
title = "Cancer stem cell–associated miRNAs serve as prognostic biomarkers in colorectal cancer",
abstract = "Chemoresistance in cancer is linked to a subset of cancer cells termed “cancer stem cells” (CSCs), and in particular, those expressing the CD44 variant appear to represent a more aggressive disease phenotype. Herein, we demonstrate that CD44v6 represents a CSC population with increased resistance to chemotherapeutic agents, and its high expression is frequently associated with poor overall survival (OS) and disease-free survival (DFS) in patients with colorectal cancer (CRC). CD44v6+ cells showed elevated resistance to chemotherapeutic drugs and significantly high tumor initiation capacity. Inhibition of CD44v6 resulted in the attenuation of self-renewal capacity and resensitization to chemotherapeutic agents. Of note, miRNA profiling of CD44v6+ spheroid-derived CSCs identified a unique panel of miRNAs indicative of high self-renewal capacity. In particular, miR-1246 was overexpressed in CD44v6+ cells, and associated with poor OS and DFS in CRC patients. We demonstrate that CD44v6+ CSCs induced chemoresistance and enhance tumorigenicity in CRC cells, and this was in part orchestrated by a distinct panel of miRNAs with dysregulated profiles. These findings suggest that specific miRNAs could serve as therapeutic targets as well as promising prognostic biomarkers in patients with colorectal neoplasia.",
author = "Shusuke Toden and Shigeyasu Kunitoshi and Jacob Cardenas and Jinghua Gu and Elizabeth Hutchins and {Van Keuren-Jensen}, Kendall and Hiroyuki Uetake and Yuji Toiyama and Ajay Goel",
year = "2019",
month = "3",
day = "21",
doi = "10.1172/jci.insight.125294",
language = "English",
volume = "4",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Cancer stem cell–associated miRNAs serve as prognostic biomarkers in colorectal cancer

AU - Toden, Shusuke

AU - Kunitoshi, Shigeyasu

AU - Cardenas, Jacob

AU - Gu, Jinghua

AU - Hutchins, Elizabeth

AU - Van Keuren-Jensen, Kendall

AU - Uetake, Hiroyuki

AU - Toiyama, Yuji

AU - Goel, Ajay

PY - 2019/3/21

Y1 - 2019/3/21

N2 - Chemoresistance in cancer is linked to a subset of cancer cells termed “cancer stem cells” (CSCs), and in particular, those expressing the CD44 variant appear to represent a more aggressive disease phenotype. Herein, we demonstrate that CD44v6 represents a CSC population with increased resistance to chemotherapeutic agents, and its high expression is frequently associated with poor overall survival (OS) and disease-free survival (DFS) in patients with colorectal cancer (CRC). CD44v6+ cells showed elevated resistance to chemotherapeutic drugs and significantly high tumor initiation capacity. Inhibition of CD44v6 resulted in the attenuation of self-renewal capacity and resensitization to chemotherapeutic agents. Of note, miRNA profiling of CD44v6+ spheroid-derived CSCs identified a unique panel of miRNAs indicative of high self-renewal capacity. In particular, miR-1246 was overexpressed in CD44v6+ cells, and associated with poor OS and DFS in CRC patients. We demonstrate that CD44v6+ CSCs induced chemoresistance and enhance tumorigenicity in CRC cells, and this was in part orchestrated by a distinct panel of miRNAs with dysregulated profiles. These findings suggest that specific miRNAs could serve as therapeutic targets as well as promising prognostic biomarkers in patients with colorectal neoplasia.

AB - Chemoresistance in cancer is linked to a subset of cancer cells termed “cancer stem cells” (CSCs), and in particular, those expressing the CD44 variant appear to represent a more aggressive disease phenotype. Herein, we demonstrate that CD44v6 represents a CSC population with increased resistance to chemotherapeutic agents, and its high expression is frequently associated with poor overall survival (OS) and disease-free survival (DFS) in patients with colorectal cancer (CRC). CD44v6+ cells showed elevated resistance to chemotherapeutic drugs and significantly high tumor initiation capacity. Inhibition of CD44v6 resulted in the attenuation of self-renewal capacity and resensitization to chemotherapeutic agents. Of note, miRNA profiling of CD44v6+ spheroid-derived CSCs identified a unique panel of miRNAs indicative of high self-renewal capacity. In particular, miR-1246 was overexpressed in CD44v6+ cells, and associated with poor OS and DFS in CRC patients. We demonstrate that CD44v6+ CSCs induced chemoresistance and enhance tumorigenicity in CRC cells, and this was in part orchestrated by a distinct panel of miRNAs with dysregulated profiles. These findings suggest that specific miRNAs could serve as therapeutic targets as well as promising prognostic biomarkers in patients with colorectal neoplasia.

UR - http://www.scopus.com/inward/record.url?scp=85069817656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069817656&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.125294

DO - 10.1172/jci.insight.125294

M3 - Article

C2 - 30895943

AN - SCOPUS:85069817656

VL - 4

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 6

M1 - e125294

ER -